CD8A and melanoma: CCR5+ MDSCs are strong inhibitors of CD8+ CTLs [59], and their presence is associated with melanoma progression: patients with melanoma have a significantly increased frequency of circulating CCR5+ MDSCs compared with healthy volunteers [60].